AU2015401587A1 - Methods of treating cancer by administering a MEK inhibitor in combination with a proteasome inhibitor - Google Patents

Methods of treating cancer by administering a MEK inhibitor in combination with a proteasome inhibitor Download PDF

Info

Publication number
AU2015401587A1
AU2015401587A1 AU2015401587A AU2015401587A AU2015401587A1 AU 2015401587 A1 AU2015401587 A1 AU 2015401587A1 AU 2015401587 A AU2015401587 A AU 2015401587A AU 2015401587 A AU2015401587 A AU 2015401587A AU 2015401587 A1 AU2015401587 A1 AU 2015401587A1
Authority
AU
Australia
Prior art keywords
cancer
mek
hsf1
cells
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015401587A
Other languages
English (en)
Inventor
Chengkai DAI
Zijian Tang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jackson Laboratory
Original Assignee
Jackson Laboratory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jackson Laboratory filed Critical Jackson Laboratory
Publication of AU2015401587A1 publication Critical patent/AU2015401587A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2015401587A 2015-07-09 2015-08-11 Methods of treating cancer by administering a MEK inhibitor in combination with a proteasome inhibitor Abandoned AU2015401587A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562190563P 2015-07-09 2015-07-09
US62/190,563 2015-07-09
PCT/US2015/044662 WO2017007495A1 (en) 2015-07-09 2015-08-11 Methods of treating cancer by administering a mek inhibitor in combination with a proteasome inhibitor

Publications (1)

Publication Number Publication Date
AU2015401587A1 true AU2015401587A1 (en) 2018-02-01

Family

ID=57685946

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015401587A Abandoned AU2015401587A1 (en) 2015-07-09 2015-08-11 Methods of treating cancer by administering a MEK inhibitor in combination with a proteasome inhibitor

Country Status (6)

Country Link
US (1) US20180369203A1 (cg-RX-API-DMAC7.html)
JP (1) JP2018520164A (cg-RX-API-DMAC7.html)
KR (1) KR20180021198A (cg-RX-API-DMAC7.html)
AU (1) AU2015401587A1 (cg-RX-API-DMAC7.html)
CA (1) CA2991777A1 (cg-RX-API-DMAC7.html)
WO (1) WO2017007495A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4087840A4 (en) 2020-01-10 2024-01-10 Immuneering Corporation MEK INHIBITORS AND THEIR THERAPEUTIC USES
CN115120731A (zh) * 2022-07-12 2022-09-30 四川大学华西医院 一种靶向蛋白酶体治疗乳腺癌的药物应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5651125B2 (ja) * 2008-12-10 2015-01-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｅｋ阻害剤に対する耐性を付与するｍｅｋ突然変異
US20130004481A1 (en) * 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
US20150071918A1 (en) * 2012-05-09 2015-03-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Peptides for the treatment of cancer
RU2708247C2 (ru) * 2013-03-05 2019-12-05 Юниверсити Оф Теннесси Рисерч Фаундейшн Соединение для лечения рака

Also Published As

Publication number Publication date
US20180369203A1 (en) 2018-12-27
WO2017007495A1 (en) 2017-01-12
CA2991777A1 (en) 2017-01-12
JP2018520164A (ja) 2018-07-26
KR20180021198A (ko) 2018-02-28

Similar Documents

Publication Publication Date Title
Tang et al. MEK guards proteome stability and inhibits tumor-suppressive amyloidogenesis via HSF1
Gallo et al. CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition
Qu et al. In vitro and in vivo antitumoral action of metformin on hepatocellular carcinoma
Cheng et al. YM155 down‐regulates survivin and XIAP, modulates autophagy and induces autophagy‐dependent DNA damage in breast cancer cells
Liu et al. Cdk5 links with DNA damage response and cancer
Ritter et al. Molecular insight into the regulation and function of MCAK
Li et al. Skp2 regulates androgen receptor through ubiquitin‐mediated degradation independent of Akt/mTOR pathways in prostate cancer
Xu et al. IU1 suppresses proliferation of cervical cancer cells through MDM2 degradation
Tyagi et al. CRISPR/Cas9-based genome-wide screening for deubiquitinase subfamily identifies USP1 regulating MAST1-driven cisplatin-resistance in cancer cells
Howell et al. Lung cancer cells survive epidermal growth factor receptor tyrosine kinase inhibitor exposure through upregulation of cholesterol synthesis
Rauch et al. Survivin antagonizes chemotherapy-induced cell death of colorectal cancer cells
Luo et al. Loss of phosphatase CTDNEP1 potentiates aggressive medulloblastoma by triggering MYC amplification and genomic instability
Zhou et al. FBXW2 inhibits prostate cancer proliferation and metastasis via promoting EGFR ubiquitylation and degradation
Huang et al. BCL-W is a regulator of microtubule inhibitor-induced mitotic cell death
Chao et al. ATM‐and ATR‐induced primary ciliogenesis promotes cisplatin resistance in pancreatic ductal adenocarcinoma
Mahmud et al. DAXX drives de novo lipogenesis and contributes to tumorigenesis
Lone et al. Non-POU Domain-Containing Octomer-Binding (NONO) protein expression and stability promotes the tumorigenicity and activation of Akt/MAPK/β-catenin pathways in human breast cancer cells
Liu et al. RETRACTED: Arginine methylation of SHANK2 by PRMT7 promotes human breast cancer metastasis through activating endosomal FAK signalling
Xie et al. Centrosomal localization of RXRα promotes PLK1 activation and mitotic progression and constitutes a tumor vulnerability
Lin et al. Polo‑like kinase 1 selective inhibitor BI2536 (dihydropteridinone) disrupts centrosome homeostasis via ATM‑ERK cascade in adrenocortical carcinoma
Hasanain et al. Microtubule disrupting agent‐mediated inhibition of cancer cell growth is associated with blockade of autophagic flux and simultaneous induction of apoptosis
US20180369203A1 (en) Methods of treating cancer by administering a mek inhibitor in combination with a proteasome inhibitor
Zhang et al. CaMKII suppresses proteotoxicity by phosphorylating BAG3 in response to proteasomal dysfunction
Wang et al. Inhibition of atypical protein kinase Cι induces apoptosis through autophagic degradation of β‐catenin in esophageal cancer cells
Chikkegowda et al. Design, synthesis, characterization, and crystal structure studies of Nrf2 modulators for inhibiting cancer cell growth in vitro and in vivo

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application